Peripheral Vascular Disease (PVD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

High cholesterol symptoms: Three serious warning signs in your feet - what to look for
HIGH cholesterol levels can lead to heart attacks and strokes but a lesser-known but equally serious complication is peripheral artery disease . There are three telltale signs in your feet that consistently high cholesterol levels have caused PAD to develop. (Source: Daily Express - Health)
Source: Daily Express - Health - April 6, 2021 Category: Consumer Health News Source Type: news

Cochrane International Mobility - Carolina Severiche Mena
Cochrane is made up of 11,000 members and over 67,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Getting involved in Cochrane ’s work means becoming part of a global community. TheCochrane International Mobility programme connects successful applicants with a placement in a host Cochrane Group, learning more about the production, use, and knowledge translation of Cochrane reviews. The prgramme offers opportunities for learning and training ...
Source: Cochrane News and Events - March 3, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

UTA researcher examining potentially less invasive treatment for peripheral artery disease
(University of Texas at Arlington) A University of Texas at Arlington bioengineer is designing a nanoparticle delivery system that will take needed plasmids to arteries in patients who are suffering from peripheral artery disease (PAD) in their arms and legs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Intradialytic Hypotension Tied to Peripheral Artery Disease
TUESDAY, Jan. 5, 2021 -- More frequent intradialytic hypotension (IDH) during hemodialysis is associated with a higher incidence of subsequent peripheral artery disease (PAD) diagnosis, according to a study published online Dec. 11 in the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 5, 2021 Category: Pharmaceuticals Source Type: news

Deaths Not Up With Paclitaxel-Coated Devices in PAD
THURSDAY, Dec. 17, 2020 -- For endovascular treatment of peripheral artery disease, paclitaxel-coated devices do not result in higher mortality than uncoated devices, according to a study published online Dec. 9 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2020 Category: Pharmaceuticals Source Type: news

Statins can save lives, are they being used?
(Mayo Clinic) People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

Statins can save lives, are they being used?
ROCHESTER, Minn. ? People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke. In a recent publication in JAMA Network Open, Mayo Clinic researchers identify trends in statin use across the U.S. among people with these diseases, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 1, 2020 Category: Databases & Libraries Source Type: news

Rivaroxaban to Prevent Brain Infarcts and Cognitive Decline Rivaroxaban to Prevent Brain Infarcts and Cognitive Decline
Might rivaroxaban with or without aspirin significantly reduce the rate of covert infarct over aspirin alone among patients with stable coronary and peripheral vascular disease?Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 25, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start
ZÜRICH, Nov. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the SirPAD (Sirolimus in Peripheral Artery Disease) tr... Devices, Interventional Concept Medical, critical limb ischemia, SirPAD , MagicTouch PTA, sirolimus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2020 Category: Pharmaceuticals Source Type: news

FDA Okays Ranger Drug-Coated Balloon for PAD FDA Okays Ranger Drug-Coated Balloon for PAD
The approval offers a tailwind for a field still coming to terms with safety concerns regarding the use of DCB in peripheral artery disease.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 4, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Boston Scientific Receives FDA Approval for the Ranger(TM) Drug-Coated Balloon
Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease MARLBOROUGH, Mass., Nov. 2, 2020 -- (Healthcare Sales & Marketing Network) -- Boston S... Devices, Interventional, FDA, Product Launch Boston Scientific, Ranger, Drug-Coated Balloon, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2020 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularization
FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD (Source: Bayer Company News)
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news